counterion raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-04 and is reviewed periodically as new material appears.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Assessed by visual inspection under ordinary laboratory lighting |
| Molecular mass | Approximately 1419 Da | Monoisotopic mass for the fifteen-residue sequence |
| Solubility class | Freely soluble in water | Stock solutions commonly prepared in water or aqueous buffer |
| Typical storage temperature | -20 °C or below, desiccated | Lyophilized powder; repeated freeze-thaw cycles are usually avoided |
| Common analytical method | Reversed-phase HPLC with UV detection | Frequently paired with mass spectrometry to confirm identity |
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
The approach is being used to try to develop vaccines for difficult-to-vaccinate-against viruses such as ebolavirus and HIV. Protein-based vaccines for COVID-19 tend to target either its spike protein or its receptor binding domain. As of 2021, the most researched vaccine platform for COVID-19 worldwide was reported to be recombinant protein subunit vaccines.
=== As biophysical models === Synthetic condensates enable complex investigation of the property of biological condensates in vivo. Using synthetic condensates, researchers showed its strong capability to buffer intracellular concentration or reduce noise. Under non-equilibirum environment of fast-growing bacteria, a synthetic organelle like RNA-based TEARS can in fact reversely amplify the noise by asymmetric division. In the same article, TEARS have been used to recruit multiple components like split GFP and present tunable composition control of biological condensates.
=== 1986 === 31 July Turbo: Once Around the Block, about British motor racing; the Ferrari F1/86 and the Imola Circuit in Emilia-Romagna in northern Italy, and Tifosi spectators; the 1984 British Grand Prix at Brands Hatch; the Motronic engine control units of Robert Bosch GmbH; Keith Duckworth, known for the Cosworth DFV, and Michael Kranefuss, head of Ford Motor Sport; Walter Hayes of Ford of Europe; Renault began turbocharged motor racing vehicles at the 1977 British Grand Prix on 16 July 1977, with the Renault RS01; Cosworth in Northampton; Beatrice Foods of the US, and Ford form an agreement in 1985, with Australian Alan Jones, with designer John Baldwin; the 1981 Italian Grand Prix and crash of John Watson; the assembled Cosworth GBA V6 engine is tested at Northampton. Produced by Patrick Uden, made by Uden Associates.
Fred Warren McLafferty (May 11, 1923 − December 26, 2021) was an American chemist known for his work in mass spectrometry. He is best known for the McLafferty rearrangement reaction that was observed with mass spectrometry. With Roland Gohlke, he pioneered the technique of gas chromatography–mass spectrometry. He is also known for electron-capture dissociation, a method of fragmenting gas-phase ions.
Sources: en.wikipedia.org
Kilishi – a version of biltong or jerky that originated in Hausaland, it is a delicacy made from cow, sheep or goat meat after the removal of bone. Kuivaliha – salted and dried meat, often reindeer meat, is a traditional food and a delicacy of northern Finland, prepared at springtime. Kulen – a kind of highly spiced, semi-dried, smoked, cured sausage from Croatia (Slavonia) and Serbia (Vojvodina). The meat undergoes fermentation-curing as well as the air-drying.
=== Conceptual development === Ilyushin began work on the aerobus in late 1969, initially by assessing the development potential of existing aircraft. An enlarged Il-62 (the Il-62-250) would have had a 30-tonne payload, 259 seats and a 6.8 metre/22 ft longer fuselage: a virtual analogue of the Douglas DC-8 "Super Sixty" series. Other proposed Il-62 modifications involved double-deck and "two fuselages side-by-side" developments. There was also a project to "civilianise" the Il-76. From March 1970 the bureau developed all-new designs under the Il-86 designation. Instead of the "appropriate technology" approach of the Il-62, these designs were to have powered controls, complex high-lift devices and advanced automation which would reduce the number of flightdeck crew. An early avanproyekt was shown to the Soviet leadership at an exhibition of civil aviation innovations at Vnukovo-2 Airport near Moscow on May 17, 1971. A scale model with the designation of "Il-86" showed the "self-loading" concept with integral boarding stairs, below-deck luggage stores, and below-deck midships galley. It had a twin-aisle interior with nine-abreast seating in a "3–3–3" layout. Ilyushin considered it politic to make the interior wider than any planned airliner except the Boeing 747. The 6.07 m (19.9 ft) fuselage diameter was partly dictated by the need to provide standing room in the underfloor luggage compartments. The Il-86 had the second-widest fuselage of any airliner until the Boeing 777. On this basis, on 9 March 1972, the bureau was asked to proceed with detailed design.
Other conditions that can result in similar symptoms include a hemothorax (buildup of blood in the pleural space), pulmonary embolism, and heart attack. A large bulla may look similar on a chest X-ray.
=== Polycythemia in neonates === Polycythemia in newborns is defined as hematocrit > 65%. Significant polycythemia can be associated with blood hyperviscosity, or thickening of the blood. Causes of neonatal polycythemia include:
=== Caveats and considerations === Some SELEX reactions can generate probes that are dependent on primer binding regions for secondary structure formation. There are aptamer applications for which a short sequence, and thus primer truncation, is desirable. An advancement on the original method allows an RNA library to omit the constant primer regions, which can be difficult to remove after the selection process because they stabilize secondary structures that are unstable when formed by the random region alone.
Sources: en.wikipedia.org
During the 2025 legislative session, Moore introduced the Housing for Jobs Act, a bill that would require local governments to automatically approve new housing developments in areas where there are 1.5 jobs for every available housing unit. After the Maryland Association of Counties expressed concerns with the bill, House lawmakers rewrote the bill that requires the state's housing secretary to set a 10-year target for housing production in the state and creates a commission to study the state's housing crisis and develop recommendations on how to address the lack of affordable housing in the state. However, this version of the bill failed to pass the General Assembly. In August 2025, Moore signed an executive order incentivizing the Maryland Department of General Services and the Maryland Department of Transportation to use their available land for housing and accelerate land awards to developers, creates housing production targets for Maryland counties, and instructs all state agencies that use housing-related permits to draft and implement plans to speed up and increase transparency around permit application processing. In January 2026, Moore said he would support three bills to spur construction and increase housing in Maryland, including proposals to encourage mixed-use development projects on state-owned land at train stations and give Maryland developers "early vesting", which would lock in a project's ground rules for five years.
In March 2013, the City of Pittsburgh filed a lawsuit in Federal court challenging the tax exempt status of UPMC as a public charity, in an effort to make UPMC to pay back taxes. The city alleged that UPMC has abused its status to avoid paying property taxes. The city dropped its lawsuit in 2014. In February 2019, the Pennsylvania Attorney General submitted legal actions against UPMC to enforce requirements for open health care access based on the non-profit status of UPMC. These actions stem from a long-standing dispute between Highmark Health and UPMC, the largest two health-care providers in Western PA. In 2011, Highmark entered a partnership with West Penn Hospital System (now Allegheny Health Network). Because of this competitive threat, UPMC declared they would not accept Highmark Blue Cross Blue Shield Insurance. In order to protect public access to health care while agreements between the two systems unwound, both UPMC and Highmark Health accepted a state-brokered consent decree. With the consent decree expiring in 2019, the Pennsylvania Attorney General attempted to negotiate continued access to care with both companies. Highmark indicated that it would accept the terms while UPMC did not. It is the failure to accept the proposal that the PA Attorney General cited as leading to the legal actions of February 2019.
PyAOP ((7-azabenzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate) is a reagent used to prepare amides from carboxylic acids and amines in the context of peptide synthesis. It can be prepared from 1-hydroxy-7-azabenzotriazole (HOAt) and a chlorophosphonium reagent under basic conditions. It is a derivative of the HOAt family of amide bond forming reagents. It is preferred over HATU, because it does not engage in side reactions with the N-terminus of the peptide. Compared to the HOBt-containing analog PyBOP, PyAOP is more reactive due to the additional nitrogen in the fused pyridine ring of the HOAt moiety. Thermal hazard analysis by differential scanning calorimetry (DSC) shows PyAOP is potentially explosive.
Von Willebrand factor, type C (VWFC or VWC)is a protein domain is found in various blood plasma proteins: complement factors B, C2, CR3 and CR4; the integrins (I-domains); collagen types VI, VII, XII and XIV; and other extracellular proteins.
Sources: en.wikipedia.org
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.
It is normally supplied as a lyophilized powder in a sealed vial. The powder dissolves readily in water, and stock solutions are typically prepared shortly before use. Cold storage is standard laboratory practice.
The letters are generally read as shorthand for body protection compound. That label comes from the original research context rather than from formal nomenclature. No standardized nonproprietary name exists for the peptide.
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.